Paul joined Agomab in 2021 as Chief Business Officer. Prior to Agomab, he was Head of Corporate Development at Galapagos from 2016-2021. In this role, he led all major transactions, investments, licensing and M&A activities for the company. Most notably, he was a key negotiator for Galapagos’ transformative $5bn strategic collaboration with Gilead Sciences. From 2013-2016, he worked at boutique investment bank Kempen & Co in Amsterdam, where he was responsible for broking and dealing of European pharma & biotech stocks to institutional investors in Europe and the US. In addition, Paul is a member of the Board of Directors at ImmuneTune (Leiden, The Netherlands). Paul studied medicine and holds a PhD in Gynaecological Oncology from the Erasmus University Medical Centre in Rotterdam, The Netherlands.